Literature DB >> 33760084

Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors.

Kartik Sehgal1,2.   

Abstract

Entities:  

Year:  2021        PMID： 33760084     DOI： 10.1001/jamanetworkopen.2021.1839

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN： 2574-3805


× No keyword cloud information.
  2 in total

1.  Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes.

Authors:  Petr Szturz; Jan B Vermorken
Journal:  Oncologist       Date:  2021-09-28

2.  Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.

Authors:  Rie Sugimoto; Takeaki Satoh; Akihiro Ueda; Takeshi Senju; Yuki Tanaka; Shinsaku Yamashita; Toshimasa Koyanagi; Tomoyuki Kurashige; Nobito Higuchi; Tsukasa Nakamura; Masatake Tanaka; Yuuki Azuma; Akari Ohno; Aritsune Ooho; Mari Ooe; Taiji Mutsuki; Koutarou Uchimura; Masami Kuniyoshi; Seiya Tada; Yoshifusa Aratake; Tsuyoshi Yoshimoto; Naoki Yamashita; Shigeru Harada; Makoto Nakamuta; Kenta Motomura; Motoyuki Kohjima
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.